Caladrius Biosciences Inc. (CLBS)
$4.23
$-0.31
(-6.83%)
As on 13-Oct-2022 09:30EDT
Market cap
$26 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0.2
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-25 Mln
-
ROE
-0.3 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
1.9
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$--
-
Face value
--
-
Shares outstanding
60,583,200
10 Years Aggregate
CFO
$-241.59 Mln
EBITDA
$-372.41 Mln
Net Profit
$-309.33 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Caladrius Biosciences (CLBS)
| 402.6 | 729.4 | 640.8 | 252.5 | 25.9 | 3.5 | -42.4 |
|
BSE Sensex*
| -9.6 | -2.7 | 2.9 | -5.0 | 5.4 | 5.7 | 10.4 |
|
Company
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
2015
|
|---|---|---|---|---|---|---|---|
|
Caladrius Biosciences (CLBS)
| -41.3 | -43.0 | -29.5 | 1.4 | 24.0 | -73.8 | -71.4 |
|
BSE Sensex
| 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 | -5.0 |
|
BSE Sensex
| 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 | -5.0 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Caladrius Biosciences (CLBS)
|
4.2 | 25.8 | 0.0 | -24.6 | -- | -28.2 | -- | 0.2 |
| 84.8 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 72.4 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 59.0 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 110.2 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 355.5 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 118.2 | 9,718.7 | 105.0 | -299.7 | -227.2 | -19.4 | -- | 6.6 | |
| 541.4 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 592.0 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 124.0 | 9,808.7 | 0.0 | -450.1 | -- | -44.6 | -- | 8.4 |
Shareholding Pattern
View DetailsAbout Caladrius Biosciences (CLBS)
Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a... recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey. Read more
-
Pres, CEO & Director
Dr. David J. Mazzo B.A. (Hons), B.Sc. (Hons.), M.Sc., Ph.D.
-
Pres, CEO & Director
Dr. David J. Mazzo B.A. (Hons), B.Sc. (Hons.), M.Sc., Ph.D.
-
Headquarters
Basking Ridge, NJ
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Caladrius Biosciences (CLBS)
What is the current share price of Caladrius Biosciences Inc (CLBS) Today?
The share price of Caladrius Biosciences Inc (CLBS) is $4.23 (NASDAQ) as of 13-Oct-2022 09:30 EDT. Caladrius Biosciences Inc (CLBS) has given a return of 25.89% in the last 3 years.
What is the current PB & PE ratio of Caladrius Biosciences Inc (CLBS)?
Since, TTM earnings of Caladrius Biosciences Inc (CLBS) is negative, P/E ratio is not available.
The P/B ratio of Caladrius Biosciences Inc (CLBS) is 0.25 times as on 13-Oct-2022, a 95 discount to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2021 |
-- |
-- |
2020 |
-- |
-- |
2019 |
-- |
-- |
2018 |
-- |
-- |
2017 |
-- |
-- |
What is the 52 Week High and Low of Caladrius Biosciences Inc (CLBS)?
The 52-week high and low of Caladrius Biosciences Inc (CLBS) are Rs -- and Rs -- as of 05-Sep-2026.
What is the market cap of Caladrius Biosciences Inc (CLBS)?
Caladrius Biosciences Inc (CLBS) has a market capitalisation of $ 26 Mln as on 13-Oct-2022. As per SEBI classification, it is a company.
Should I invest in Caladrius Biosciences Inc (CLBS)?
Before investing in Caladrius Biosciences Inc (CLBS), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.